Información de la revista
Vol. 48. Núm. 4.
Páginas 238-240 (abril 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 48. Núm. 4.
Páginas 238-240 (abril 2024)
Scientific Letter
Acceso a texto completo
Effect of vitamin C, thiamine and hydrocortisone in critically ill septic patients. The Metabolic Resus RCT
Efecto de la vitamina C, tiamina e hidrocortisona en pacientes críticos sépticos
Visitas
609
Juliana Gonzalez Londoñoa,b,
Autor para correspondencia
, Claudia Vera Chingc, Patricia Sebastian Cernudac, Josep Miquel Morales Pedrosaa,b, Carol Lorenciob,c, Josep-Maria Sirventa,b,c
a Critical Care Department, Hospital Santa Caterina, Salt, Girona, Spain
b Institut d’Investigació Biomédica de Girona Dr. Josep Trueta, Girona, Spain
c Critical Care Department, Hospital Universitario de Girona Doctor Josep Trueta, Girona, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (1)
Table 1. Participant characteristics (Treatment vs. Control group).
Texto completo
To the editor:

Sepsis and septic shock continue to be the most frequent reason for admission to intensive care units, affecting millions of people around the world. Global incidence has been estimated between 250 and 500 cases/100.000 cases per year1 and can lead up to 6% of total hospital admissions only in the United States.2. Up to 51.1% require Intensive Care Unit (ICU) admission, reaching mortality rates of 30% and even 50% in cases of septic shock.3 Additionally, septic patients present short- and long-term complications, which lead to decreased quality of life and increased 5-year mortality.4 Our research group described an annual sepsis incidence in Catalonia of 264.1 per 100.000 inhabitants/year, and it increased every year, going from 144.5 in 2005 to 410.1 in 2019.5

In the constant search for a “cure” for sepsis, Marik et al. suggested that the early use of intravenous vitamin C, together with corticosteroids and thiamine, are effective in preventing progressive organ dysfunction, including acute kidney injury, and in reducing the mortality of patients with severe sepsis and septic shock.6 Despite the limitations of the study, their results and interesting pathophysiological argument, raised enough enthusiasm to put in motion several studies looking to reproduce his findings. Until today, there are no studies that support Dr Marik’s findings, and the use of vitamin C, corticosteroids and thiamine is not supported in current sepsis management recommendations.7

We performed a phase III, randomized, open, parallel group pilot study, which aimed to study 28-day mortality in patients with severe sepsis or septic shock treated according to current guidelines vs. patients treated with vitamin C, thiamine, and hydrocortisone added to usual treatment. As it was a pilot study, sample size calculation was not required; however, an N of 20 patients per group was expected for the time set for the study.

Subjects were patients with septic shock admitted to the ICU of 2 different hospitals in the same sanitary region that met the criteria to enter the study and signed the informed consent. Patients were randomized into a treatment and a control group. Randomization was aleatory, using the nQuery program.

Study was approved by the hospital’s ethics committee and registered in ClinicalTrials.gov (Identifier: NCT04111822). Reasons for exclusions were pregnancy, chronic use of vitamin C, thiamine or hydrocortisone, existing immunosuppression, and a defined limitation in ICU therapy upon intake.

Demographic data, sepsis biomarkers and other aspects of treatment were collected during the first 7 days, final outcomes were also included in the database.

The primary endpoint was 28-day mortality, and the secondary endpoints were number of ICU days, mechanical ventilation days and vasopressor dose.

Descriptive statistics and comparative analyses between treatment vs. control group and survived and dead patients were made using the chi-square test, Student t-test or nonparametric estimation (Mann-Whitney U test), when appropriate. We designed Kaplan-Meier survival curves comparing treatment vs. control group. P value of <0.05 were considered statistically significant.

A total of 24 patients were included in the pilot study, unfortunately, by March 2020 the COVID-19 pandemic forced us to put the study on pause due to obvious reasons. By the time patient recruiting could be resumed, our preliminary analysis combined with the results of several studies, mainly the VICTAS,8 VITAMIN9 and the ACTS RCT10 led us to decide termination of the trial. This decision was based on the data of these studies and a preliminary analysis of our data that showed futility of the treatment. Trial termination was decided on what we mainly considered were ethical reasons.

Baseline characteristics were generally similar between the treatment group and the control group (Table 1). Six patients died (25%) during ICU stay, there was no statistically significant difference in the mortality between the treatment and the control group (Fig. 1), these results are similar to the ones of the ACTS RCT,10 and even though the VITAMINS RCT9 administered hydrocortisone to the control group, they also found no statistically significant differences in mortality between the two groups.

Table 1.

Participant characteristics (Treatment vs. Control group).

Characteristics  Total (n = 24)  Treatment group(n = 12)  Control group(n = 12)  p 
Age, mean, y (SD)  64.8 (13)  63.3 (11.3)  66.3 (14.7)  0.58 
Male, No. (%)  13 (54)  7 (58.3)  6 (50.0)  0.68 
Diabetes, No. (%)  7 (29.2)  3 (25)  4 (33.3)  0.65 
Hypertension, No. (%)  16 (66.7)  8 (66.7)  8 (66.7) 
Neoplasic disease, No. (%)  4 (16.7)  1 (8.3)  3 (25)  0.27 
COPD, No. (%)  3 (12.5)  1 (8.3)  2 (16.7)  0.53 
Obesity, No. (%)  10 (41.7)  5 (41.7)  5 (41.7) 
Diagnose No. (%)         
Pneumonia  8 (33.3)  6 (50)  2 (16.7)  0.26 
Abdominal sepsis  5 (20.8)  1 (8.3)  4 (33.3)   
Urinary tract sepsis  5 (20.8)  2 (16.7)  3 (25)   
Other  6 (25)  3 (25)  3 (23)   
Clinical values, mean (SD)         
APACHE II score  26.3 (16.1)  28.7 (21.6)  24 (8)  0.48 
SAPS II score  60.5 (20.4)  61 (23.6)  60 (17.7)  0.29 
Initial SOFA score  9.8 (2.1)  9.8 (2.2)  10 (2)  0.85 
Lactate on admission, mg/dl  27.4 (17.6)  23.6 (16.8)  31 (18.3)  0.3 
Lactate 6 hours, mg/dl  26.8 (19.1)  28.3 (24)  25.2 (13)  0.7 
Lactate 24 hours, mg/dl  26.6 (27.9)  27 (33)  26.2 (23)  0.9 
Noradrenaline dose intake, mcg/k/min  0.5 (0.5)  0.5 (0.5)  0.45 (0.42)  0.55 
Noradrenaline dose day 3, mcg/k/min  0.3 (0.4)  0.4 (0.4)  0.2 (0.3)  0.48 
Noradrenaline dose day 7, mcg/k/min  0.3 (0.5)  0.4 (0.7)  0.1 (0.1)  0.29 
Urinary output day 1, L/24 hours  1.4 (0.8)  1.2 (0.8)  1.7 (0.7)  0.22 
PCR at intake, mg/dl  41 (41.4)  49.2 (57.5)  32.8 (11.2)  0.13 
PCR day 3, mg/dl  26.1 (28.5)  32.2 (39)  20 (10.5)  0.05 
Procalcitonin on admission, ng/ml  26 (33.9)  25.8 (37.3)  31.7 (9)  0.9 
Procalcitonin day 3, ng/ml  13.6 (18.9)  8.6 (9.6)  19 (24.8)  0.2 
Creatinine at intake, mg/dl  1.8 (1.4)  2.1 (2)  1.4 (0.5)  0.28 
Creatinine day 3, mg/dl  1.4 (0.8)  1.4 (0.8)  1.4 (0.9)  0.86 
Creatinine day 7, mg/dl  1.1 (0.8)  1.5 (1)  0.7(0.5)  0.09 
White blood cell count intake, 10³/mcl  21.4 (11.3)  16 (14.4)  18.4 (10.7)  0.65 
White blood cell count day 3, 10³/mcl  17 (9.3)  19.3 (10.6)  14.7 (7.6)  0.26 
White blood cell count day 7, 10³/ mcl  18 (5.7)  20.3 (5.6)  15.8 (5.3)  0.13 
Platelets on admission, 10³/ mcl  202 (140.5)  214 (180.8)  189.8 (91)  0.68 
Platelets day 3, 10³/ mcl  174 (166.4)  205 (223.6)  142.6 (77.4)  0.39 
Platelets day 7, 10³/ mcl  260 (148.5)  261.3 (183)  259.1 (124.2)  0.97 
Bilirubin on admission, mg/dl  1.2 (1)  1.3 (1)  1.2 (1)  0.86 
Bilirubin day 3, mg/dl  0.7 (0.7)  0.7 (0.7)  0.7 (0.6) 
Bilirubin day 7, mg/dl  0.5 (0.2)  0.45 (0.2)  0.5 (0.3)  0.36 
Dialysis, No. (%)  8 (33.3)  5 (41.7)  3 (25)  0.38 
Need of surgical procedure, No. (%)  11 (45.8)  2 (16.7)  9 (75)  0.00 
Mechanical ventilation, days (SD)  14.5 (14.8)  8.0 (7)  22.3 (18.2)  0.04 
ICU stay, days (SD)  18.5 (13)  12.3 (10)  24.8 (23.5)  0.11 
Hospital stay, days (SD)  32 (30.5)  24 (23.8)  40.1 (35.3)  0.2 
28-day mortality, No, (%)  6 (25)  3 (25)  3 (25)  1.0 
Figure 1.

Kaplan-Meier survival curve comparing treatment vs. control group (NS).

(0.11MB).

We also found no statistically significant difference in the decrease of vasopressor dose during the first 7 days of treatment, results that are equivalent to the ones of the VITAMINS (16) and the VICTAS8 studies. Patients on the control group required more surgical procedures than the treatment group: 75% vs. 16.7% (P = 0.00), given the number of patients of this study, we believe that this finding would probably disappear on a larger group.

Patients in the intervention group spent less time on mechanical ventilation than the control group. The mean number of mechanical ventilation days was 8.0 (SD 7.0) for the treatment group vs. 22.3 (SD 18.2) for the control group (P = 0.04). Other studies have found no statistically significant differences in mechanical ventilation free days, we consider that larger studies and larger samples have provided data that does not support this finding.

The authors consider that even though the results are similar to recent larger studies, they should not be considered comparable to them, because of the obvious limitations of our study. Even though our data showed a difference in mechanical ventilator days, we consider the sample was not big enough to make any affirmations and there are larger studies that did not find these differences.

In conclusion, in our series, the combination of intravenous vitamin C, thiamine and hydrocortisone compared to a control group did not show statistically significant differences in vasopressor dose or 28-day mortality in critically ill patients.

Conflict of interest

The authors declare that there are no conflicts of interest related to this article.

Financing

There were no public or private funding sources for carrying out this study.

References
[1]
C. Fleischmann, A. Scherag, N.K. Adhikari, C.S. Hartog, T. Tsaganos, P. Schlattmann, et al.
Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations.
Am J Respir Crit Care Med, 193 (2016), pp. 259-272
[2]
D.C. Angus, W.T. Linde-Zwirble, J. Lidicker, G. Clermont, J. Carcillo, M.R. Pinsky, et al.
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
Crit Care Med, 29 (2001), pp. 1303-1310
[3]
D. Annane, P. Aegerter, M.C. Jars-Guincestre, B. Guidet.
CUB-Réa Network. Current epidemiology of septic shock: the CUB-Réa Network.
Am J Respir Crit Care Med, 168 (2003), pp. 165-172
[4]
S. Yende, S. Austin, A. Rhodes, S. Finfer, S. Opal, T. Thompson, et al.
Long-term quality of life among survivors of severe sepsis: analyses of two international trials.
Crit Care Med, 44 (2016), pp. 1461-1467
[5]
C. Lorencio Cárdenas, J.C. Yébenes, E. Vela, M. Clèries, J.M. Sirvent, C. Fuster-Bertolín, et al.
Trends in mortality in septic patients according to the different organ failure during 15 years.
[6]
P.E. Marik, V. Khangoora, R. Rivera, M.H. Hooper, J. Catravas.
Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study.
Chest, 151 (2017), pp. 1229-1238
[7]
L. Evans, A. Rhodes, W. Alhazzani, M. Antonelli, C.M. Coopersmith, C. French, et al.
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock.
Crit Care Med, 49 (2021), pp. 1063-1143
[8]
J.E. Sevransky, R.E. Rothman, D.N. Hager, G.R. Bernard, S.M. Brown, T.G. Buchman, et al.
Effect of vitamin C, thiamine, and hydrocortisone on ventilator- and vasopressor-free days in patients with sepsis: the VICTAS randomized clinical trial.
JAMA, 325 (2021), pp. 742-750
[9]
T. Fujii, N. Luethi, P.J. Young, D.R. Frei, G.M. Eastwood, C.J. French, et al.
Effect of vitamin C, hydrocortisone, and thiamine vs hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the VITAMINS randomized clinical trial.
JAMA, 323 (2020), pp. 423-431
[10]
A. Moskowitz, D.T. Huang, P.C. Hou, J. Gong, P.B. Doshi, A.V. Grossestreuer, et al.
Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial.
JAMA, 324 (2020), pp. 642-650
Copyright © 2023. Elsevier España, S.L.U. y SEMICYUC
Descargar PDF
Idiomas
Medicina Intensiva
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?